Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Elizabeth M. Sagatys"'
Publikováno v:
Human Pathology: Case Reports, Vol 24, Iss , Pp 200513- (2021)
Primary anaplastic large cell lymphoma (ALCL) of the central nervous system (CNS) is a rare entity. Most primary CNS lymphomas are of B-cell origin, including those associated with HIV. We report a case of a 29-year-old woman who presented with worse
Externí odkaz:
https://doaj.org/article/96c53b4f13a84f9f95b958b4c516e107
Autor:
Brian C. Betts, Frederick L. Locke, Elizabeth M. Sagatys, Joseph Pidala, Kelly Walton, Meghan Menges, Jordan Reff, Asim Saha, Julie Y. Djeu, John V. Kiluk, Marie C. Lee, Jongphil Kim, Chang Won Kang, Chih-Hang Anthony Tang, Jeremy Frieling, Conor C. Lynch, Alan List, Paulo C. Rodriguez, Bruce R. Blazar, Jose R. Conejo-Garcia, Juan R. Del Valle, Chih-Chi Andrew Hu, Claudio Anasetti
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Acute graft- vs. -host disease (GVHD) is an important cause of morbidity and death after allogeneic hematopoietic cell transplantation (HCT). We identify a new approach to prevent GVHD that impairs monocyte-derived dendritic cell (moDC) alloactivatio
Externí odkaz:
https://doaj.org/article/d7d53dab35a0449b90de1bf45bb8064e
Autor:
David A. Sallman, Jason Brayer, Elizabeth M. Sagatys, Caroline Lonez, Eytan Breman, Sophie Agaugué, Bikash Verma, David E. Gilham, Frédéric F. Lehmann, Marco L Davila
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
Externí odkaz:
https://doaj.org/article/9b7b7be87bdb4d579a61dcfd61aa11be
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
Impact of JAK2/mTOR blockade on human NK cell function and proliferation. A) Graph shows the cytolytic activity ({plus minus}SEM) of NK cells after 4 hours of culture with K562 target cells, while exposed to DMSO, ruxolitinib (lμM), pacritinib (1.25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472281a0dfd04f48df3f41ca55b74674
https://doi.org/10.1158/1078-0432.22479069
https://doi.org/10.1158/1078-0432.22479069
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
The table shows the pharmacokinetic analysis of pacritinib concentration over time.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287a2018ed8b31a4ea62f70576bb4ae5
https://doi.org/10.1158/1078-0432.22479045.v1
https://doi.org/10.1158/1078-0432.22479045.v1
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
The table shows pacritinib adherence during treatment period according to dose level on the PAC/SIR/TAC phase I trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c0512d1dde987b3f6dfc7401c1d8eb
https://doi.org/10.1158/1078-0432.22479048
https://doi.org/10.1158/1078-0432.22479048
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
Safety measures monitored on trial including (A) QTcF, (B) cardiac ejection fraction, (C) prothrombin time, (D) partial thromboplastin time, (E) and thrombin time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bfdf466333ef4fcb86726b4ae47298a
https://doi.org/10.1158/1078-0432.22479075
https://doi.org/10.1158/1078-0432.22479075
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
The table shows adverse events per CTCAE version 5 encountered during the PAC/SIR/TAC phase I trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e35f61516a38b0fac0e5b5e342dda4
https://doi.org/10.1158/1078-0432.22479054
https://doi.org/10.1158/1078-0432.22479054
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
The table shows the maximum chronic GVHD organ involvement and overall score per NIH Diagnosis and Staging Criteria through full extent of study follow up on the PAC/SIR/TAC phase I trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::046cb21a97dcc823224cee8489e75dc6
https://doi.org/10.1158/1078-0432.22479039.v1
https://doi.org/10.1158/1078-0432.22479039.v1
Autor:
Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, Joseph Pidala
CD4+ T cell Aurora kinase A activation as a GVHD resistance mechanism. A) Graph shows frequency of CD4+, pHistone 3 serine 10+ (pH3ser10) (downstream of CD28, and parallel to mTOR) T cells (mean{plus minus} SEM) at day +21 among patients treated on d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cadd496a9473217ea1a06018fb4a0ff6
https://doi.org/10.1158/1078-0432.22479063.v1
https://doi.org/10.1158/1078-0432.22479063.v1